Inspire Pharmaceuticals (ISPH) Inactive 10-K2010 FY Annual report

Filed: 25 Feb 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: absolute, ACA, AllerganProlacriacommercialization, AMP, andDiquasthat, andPatadaycurrently, Andrew, aProlacriaproduct, Aton, AzaSiteof, benchmark, bifurcated, bottle, Brier, carrier, comparingAzaSiteto, counter, Creek, deadline, debarment, decree, Diquasophthalmic, double, driven, DSU, easier, expend, exploratory, Finorga, forRestasisin, France, futureProlacriadevelopment, gradual, hereinafter, hydrochloride, includingProlacria, installing, Johnson, jurisdictional, Koven, licensure, manufactureAzaSiteand, mentioned, modification, nationwide, NC, nonsubstantive, Novasep, Obama, ofAzaSiteduring, ofAzaSitethat, ofElestatwith, offerProlacriacommercialization, OIG, online, ourAzaSiteinventory, Parent, Partnership, passed, Patanol, PharmaForce, photographic, PHS, predicate, premium, procuring, Raleigh, raw, relieve, relocated, repackaging, Republic, researchingAzaSite, RSU, shortfall, smoothing, specialty, spoilage, step, stepped, straight, stream, subsidiary, teaching, tenant, tentative, theProlacriaclinical, thereof, therewith, tiered, toProlacriain, unapproved, unusable, user, VA, vacated, Valeant, warehousing, wrongful, Zymaxid

Removed: absence, academic, accelerate, accelerated, accelerating, acceleration, adjacent, aged, airflow, ancillary, andTOBI, approveProlacria, Asia, aspect, aztreonam, Bank, bind, Blvd, Boehringer, break, breaking, broker, budgeted, capability, carcinogenicity, commercializeProlacriaworldwide, communication, comparing, concomitant, confirm, consignment, consistent, constant, contingency, convertible, credited, debit, decelerating, dedicated, Deduction, defer, dehydrated, delivered, demonstrated, depository, device, discounting, disposed, disrupting, DNA, dollar, Electric, embedded, emerge, emerging, Emperor, essentially, exchanged, expertise, feature, field, fluctuating, function, gene, Genentech, Gilead, goal, guaranteed, humor, hypertonic, IC, identifying, inElestat, Ingelheim, inhalation, inhaled, innovative, insolvent, insufficient, internationally, intervention, intraocular, jet, lending, lung, Lynch, measuring, mechanism, Merrill, meshwork, mg, minimal, nebulizer, newly, obstruction, ofElestatwill, ofProlacriaand, orProlacria, outflow, oversee, par, Park, partnering, portable, preceding, prefer, prepaid, prepayment, preserved, progressive, protein, Pulmozyme, ratio, reached, relationship, researching, resold, resolution, respiratory, retired, Royal, saline, satisfactory, seized, sellProlacria, sentence, Silicon, smaller, stocking, sustaining, systemic, thatProlacria, thickened, toElestat, trabecular, transportation, treated, Triangle, uncured, validated, Valley, vial, withProlacria, withZithromax

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ISPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Inspire Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2010, as filed with the Securities and Exchange Commission (the “Report”), I, Adrian Adams, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 25, 2011

/s/ ADRIAN ADAMS

Adrian Adams

President & Chief Executive Officer

(principal executive officer)